MX2019004499A - Sistemas de replicón de virus recombinante y usos de estos. - Google Patents
Sistemas de replicón de virus recombinante y usos de estos.Info
- Publication number
- MX2019004499A MX2019004499A MX2019004499A MX2019004499A MX2019004499A MX 2019004499 A MX2019004499 A MX 2019004499A MX 2019004499 A MX2019004499 A MX 2019004499A MX 2019004499 A MX2019004499 A MX 2019004499A MX 2019004499 A MX2019004499 A MX 2019004499A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant virus
- interest
- virus replicon
- modified
- replicon systems
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409228P | 2016-10-17 | 2016-10-17 | |
| PCT/US2017/054928 WO2018075235A1 (en) | 2016-10-17 | 2017-10-03 | Recombinant virus replicon systems and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019004499A true MX2019004499A (es) | 2019-11-18 |
Family
ID=60153459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004499A MX2019004499A (es) | 2016-10-17 | 2017-10-03 | Sistemas de replicón de virus recombinante y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11364310B2 (enExample) |
| EP (1) | EP3526332B1 (enExample) |
| JP (2) | JP7382230B2 (enExample) |
| KR (1) | KR102718353B1 (enExample) |
| CN (1) | CN110073002B (enExample) |
| AU (1) | AU2017347725B2 (enExample) |
| BR (1) | BR112019007433A2 (enExample) |
| CA (1) | CA3040264A1 (enExample) |
| ES (1) | ES2993107T3 (enExample) |
| MX (1) | MX2019004499A (enExample) |
| WO (1) | WO2018075235A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| AU2017347725B2 (en) | 2016-10-17 | 2024-01-04 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| JP7494117B2 (ja) | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
| SG11202007606QA (en) | 2018-02-17 | 2020-09-29 | Flagship Pioneering Innovations V Inc | Compositions and methods for membrane protein delivery |
| AU2019359204B2 (en) * | 2018-10-08 | 2024-12-05 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020255055A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP4085130A4 (en) | 2019-12-31 | 2024-04-10 | Elixirgen Therapeutics, Inc. | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| US20230096378A1 (en) | 2020-03-12 | 2023-03-30 | Institute For Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
| GB2605538B (en) | 2020-03-23 | 2024-06-26 | Hdt Bio Corp | Compositions and methods for delivery of RNA |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| WO2021229448A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Rna replicon encoding a stabilized corona virus spike protein |
| CA3183500A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| PH12023550030A1 (en) | 2020-07-08 | 2024-03-11 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| US20230398200A1 (en) * | 2020-07-31 | 2023-12-14 | Replicate Bioscience, Inc. | Modified chikungunya viruses and sindbis viruses and uses thereof |
| BR112023002642A2 (pt) | 2020-08-14 | 2023-04-04 | Arcturus Therapeutics Inc | Método para liofilizar nanopartículas lipídicas |
| CN112458064A (zh) * | 2020-11-20 | 2021-03-09 | 广西大学 | 盖他病毒全长感染性克隆、复制子系统及其制备和应用 |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| JP2024527345A (ja) * | 2021-07-09 | 2024-07-24 | リプリケイト バイオサイエンス，インコーポレイティド | 改変東部ウマ脳炎ウイルス、自己複製ｒｎａ構築物、及びその使用 |
| JP2024535353A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | 感染性疾患に対するｒｎａワクチン |
| CA3232725A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Cancer therapy compositions and uses thereof |
| JP2024535351A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | 乾燥ナノ粒子組成物 |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法 |
| PE20251395A1 (es) | 2022-05-12 | 2025-05-22 | Msd Int Business Gmbh | Proteinas de fusion de hmpv de prefusion estabilizadas |
| WO2024008192A2 (zh) * | 2022-07-08 | 2024-01-11 | 嘉晨西海(杭州)生物技术有限公司 | 经修饰的自复制mRNA |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| AU639428B2 (en) | 1988-12-01 | 1993-07-29 | Imclone Systems, Inc. | Synthetic interleukin-6 |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| ATE227118T1 (de) | 1993-08-02 | 2002-11-15 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
| DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
| US6110161A (en) | 1997-04-03 | 2000-08-29 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
| CA2294793A1 (fr) | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede |
| US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
| JP2003505114A (ja) | 1998-07-13 | 2003-02-12 | ジェネトロニクス、インコーポレーテッド | パルス電場による皮膚および筋肉を標的とした遺伝子治療 |
| US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
| WO2002020721A2 (en) | 2000-09-07 | 2002-03-14 | University Of North Carolina At Chapel Hill | Vectors derived from south african arbovirus no. 86 |
| US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| EP1363660A4 (en) | 2001-02-01 | 2006-06-21 | Univ Johns Hopkins | HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN |
| ATE354260T1 (de) | 2001-07-19 | 2007-03-15 | Ericsson Telefon Ab L M | Verfahren und vorrichtung für die lösung der nummernübertragbarkeit am ursprungsort |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| AU2003297860A1 (en) | 2002-12-12 | 2004-07-09 | The Board Of Regents Of The University Of Texas System | Large scale production of packaged alphavirus replicons |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
| DK1729848T3 (en) | 2004-03-08 | 2015-07-20 | Ichor Medical Systems Inc | IMPROVED APPARATUS FOR ELECTRICAL COMMUNICATED administration of therapeutic agents |
| CN101548014B (zh) | 2006-06-06 | 2012-07-04 | 墨尔本保健公司 | 抗病毒抗性突变的检测和应用 |
| EP2062246A4 (en) * | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| ES2993941T3 (en) | 2006-10-17 | 2025-01-14 | Inovio Pharmaceuticals Inc | Electroporation devices for electroporation of cells in mammals |
| EP2097538A4 (en) | 2006-12-07 | 2011-11-30 | Switchgear Genomics | TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| EP2222336A2 (en) | 2007-10-29 | 2010-09-01 | GENimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
| NZ598000A (en) | 2009-08-07 | 2013-10-25 | Transgene Sa | Composition for treating hbv infection |
| DK2519266T3 (da) | 2009-12-31 | 2017-11-06 | Medigen Inc | Infektiøse DNA vacciner mod Chikungunya virus |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| EP2655621B1 (en) | 2010-12-20 | 2018-05-23 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| KR101942372B1 (ko) | 2011-02-11 | 2019-04-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | B형 간염 바이러스 코어 단백질을 암호화하는 핵산 분자 및 이를 포함하는 백신 |
| EP3473296B1 (en) | 2011-06-28 | 2020-08-05 | Inovio Pharmaceuticals, Inc. | A minimally invasive dermal electroporation device |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP3178505B1 (en) | 2012-12-13 | 2018-05-02 | Panasonic Healthcare Holdings Co., Ltd. | Medicament injection device |
| WO2014170493A2 (en) * | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| CN105473157A (zh) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | 组合疫苗 |
| WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| US10166288B2 (en) | 2014-10-01 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| CN116196403A (zh) | 2015-08-03 | 2023-06-02 | 美国卫生和人力服务部 | Brachyury缺失突变体、编码该缺失突变体的非酵母载体及其用途 |
| WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| EP3436139B1 (en) | 2016-03-28 | 2025-04-30 | PapiVax Biotech, Inc. | METHOD AND APPARATUS FOR ADMINISTERING THERAPEUTIC AGENTS |
| WO2017176319A1 (en) | 2016-04-06 | 2017-10-12 | University Of Washington | Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| AU2017347725B2 (en) * | 2016-10-17 | 2024-01-04 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| JP6613399B2 (ja) | 2017-06-05 | 2019-12-04 | 株式会社ビークル | Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子 |
| CN111542340B (zh) | 2017-11-16 | 2023-12-19 | 华盛顿大学 | 治疗性乙型肝炎病毒(hbv)疫苗 |
| JOP20200153A1 (ar) | 2017-12-19 | 2022-10-30 | Janssen Sciences Ireland Unlimited Co | لقاحات التهاب الكبد الفيروسي b (hbv) واستخداماته |
| JP7494117B2 (ja) * | 2018-01-19 | 2024-06-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えレプリコン系を使用する免疫応答の誘導および増強 |
-
2017
- 2017-10-03 AU AU2017347725A patent/AU2017347725B2/en active Active
- 2017-10-03 US US15/723,658 patent/US11364310B2/en active Active
- 2017-10-03 ES ES17787724T patent/ES2993107T3/es active Active
- 2017-10-03 EP EP17787724.8A patent/EP3526332B1/en active Active
- 2017-10-03 CA CA3040264A patent/CA3040264A1/en active Pending
- 2017-10-03 MX MX2019004499A patent/MX2019004499A/es unknown
- 2017-10-03 CN CN201780075817.7A patent/CN110073002B/zh active Active
- 2017-10-03 JP JP2019520535A patent/JP7382230B2/ja active Active
- 2017-10-03 KR KR1020197013847A patent/KR102718353B1/ko active Active
- 2017-10-03 WO PCT/US2017/054928 patent/WO2018075235A1/en not_active Ceased
- 2017-10-03 BR BR112019007433A patent/BR112019007433A2/pt unknown
-
2022
- 2022-06-13 US US17/806,581 patent/US20230126773A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101803A patent/JP2023134488A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3040264A1 (en) | 2018-04-26 |
| CN110073002A (zh) | 2019-07-30 |
| EP3526332C0 (en) | 2024-06-26 |
| JP7382230B2 (ja) | 2023-11-16 |
| KR102718353B1 (ko) | 2024-10-15 |
| US20230126773A1 (en) | 2023-04-27 |
| JP2019530466A (ja) | 2019-10-24 |
| US20180104359A1 (en) | 2018-04-19 |
| AU2017347725B2 (en) | 2024-01-04 |
| JP2023134488A (ja) | 2023-09-27 |
| WO2018075235A1 (en) | 2018-04-26 |
| US11364310B2 (en) | 2022-06-21 |
| BR112019007433A2 (pt) | 2019-07-02 |
| CN110073002B (zh) | 2024-06-11 |
| AU2017347725A1 (en) | 2019-05-09 |
| EP3526332B1 (en) | 2024-06-26 |
| EP3526332A1 (en) | 2019-08-21 |
| KR20190082226A (ko) | 2019-07-09 |
| ES2993107T3 (en) | 2024-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019004499A (es) | Sistemas de replicón de virus recombinante y usos de estos. | |
| MX391337B (es) | Sistemas de replicón de arterivirus recombinantes y usos de estos. | |
| MX2019006467A (es) | Composiciones y métodos para mejorar la expresión génica. | |
| CL2021002739A1 (es) | Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| PH12019500280A1 (en) | Trimer stabilizing hiv envelope protein mutations | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| MX2018011384A (es) | Arn de replicacion en trans. | |
| MX2018016114A (es) | Una novedosa fructosa-6-fosfato-3-epimerasa termoestable y un procedimiento para producir alulosa mediante el uso de la misma. | |
| EP3950941A3 (en) | Dnase polypeptide variants | |
| MX372992B (es) | Vector de virus adeno-asociado. | |
| AU2015286820A8 (en) | Stabilization of poly(A) sequence encoding DNA sequences | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| NZ730802A (en) | Therapeutic hpv16 vaccines | |
| MX2019000082A (es) | Una novedosa tagatosa-6-fosfato fosfatasa termoestable y un procedimiento para producir tagatosa usando la misma. | |
| MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
| ZA202100384B (en) | Influenza virus hemagglutinin mutants | |
| MX2016009149A (es) | Variantes mejoradas de enzimas. | |
| PH12018500155A1 (en) | Recombinant orf virus vector | |
| EP4368702A3 (en) | Method of enhancing rna expression in a cell | |
| NZ759538A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| PH12020500526A1 (en) | Paramyxoviridae expression system | |
| PH12019500578A1 (en) | New promoters | |
| PH12018501532A1 (en) | Cancer vaccines | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| SG11201902998SA (en) | PROMOTER OF Hspa5 GENE |